

References

S-147

- 1 . Han Y, Li J, Han S, Jia S, Zhang Y, Zhang W. Diagnostic value of endoscopic appearance during ductoscopy in patients with pathological nipple discharge. *BMC Cancer*. 2017;17(1):300.
- 2 . Do Canto L, Marian C, Haddad B, et al. MicroRNA analysis of breast ductal fluid in breast cancer patients. *International Journal Of Oncology*. 2016;48(5):2071-2078.
- 3 . Matos Do Canto L, Marian C, Haddad B, et al. Metabolomic profiling of breast tumors using ductal fluid. *International Journal Of Oncology*. 2016; 49(6):2245-2254.
4. American Society of Breast Surgeons. Consensus statement on screening mammography. October 29, 2015.
5. Chan AA, Bashir M, Rivas MN, et al. Characterization of the microbiome of nipple aspirate fluid of breast cancer survivors. *Sci Rep*. 2016; 21;6:28061.
6. Chatterton RT, Heinz RE, Fought AJ, et al. Nipple aspirate fluid hormone concentrations and breast cancer risk. *Horm Cancer*. 2016; 7(2):127–136.
7. Hornberger J, Chen SC, Li Q, et al. Proliferative epithelial disease identified in nipple aspirate fluid and risk of developing breast cancer: a systematic review. *Curr Med Res Opin*. 2015;31(2):253-62.
8. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Breast cancer screening and diagnosis. 2018.
9. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Breast cancer risk reduction. 2018.
10. Shaheed SU, Tait C, Kyriacou K, et al. Evaluation of nipple aspirate fluid as a diagnostic tool for early detection of breast cancer. *Clin Proteomics*. 2018; 11;15:3.